Complete Genomics, a struggling DNA sequencing company in Silicon Valley, said on Monday that it had agreed to be acquired for USD 117.6 million by BGI-Shenzhen, a Chinese company that operates the world’s largest sequencing operation. The deal will need antitrust clearance, because of two key players in the DNA sequencing business in a highly capital intensive and research intensive industry, as well as clearance from a national security review by the Committee on Foreign Investment in the United States. It also requires approval from certain governmental authorities in China.
Featured News
Supreme Court Lets CREXi Antitrust Case Against CoStar Move Forward
Mar 23, 2026 by
CPI
Oregon Just Passed the Country’s Toughest Chatbot Law. Your Company May Already Be Breaking It.
Mar 23, 2026 by
CPI
Newsmax, DirecTV Join Challenge to FCC’s Nexstar-Tegna Decision
Mar 23, 2026 by
CPI
House Committee Readies Hearing on Tokenized Securities Trading Rules
Mar 23, 2026 by
CPI
Vinson & Elkins Launches Brussels Office With Hire of Hogan Lovells Antitrust Partner
Mar 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data-Driven Competition
Mar 19, 2026 by
CPI
Data-Driven Competition: Implications For Enforcement and Merger Control
Mar 19, 2026 by
Alexandre de Corniere & Greg Taylor
From Tipping to Trustees: Why Data-Driven Markets Require Institutional Design, Not Optimization
Mar 19, 2026 by
Jens Prüfer & Paul de Bijl
Data Barriers to Entry: What We’ve Learned About Spotting Them and What We Still Don’t Know About Solutions
Mar 19, 2026 by
Bruno Carballa-Smichowski
When the Perfect Is the Enemy of the Good: Price Discrimination, Affordability, Precarity and Market Dynamism
Mar 19, 2026 by
Dan Ciuriak